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1. Introduction  
The measurement of trace amounts of physiologically active small molecules (for example, 
lipids, drugs, other synthetic chemicals and metals) is critical for both clinical and 
environmental analyses. Most small molecules can be analyzed using highly sophisticated 
analytical techniques, including high pressure liquid chromatography (HPLC), gas 
chromatography (GC), and inductively coupled plasma atomic emission spectroscopy 
(ICPAES). However, these methods require extensive purification, experienced technicians, 
and expensive instruments and reagents. Immunoassays offer an alternative to these 
instrument-intensive methods. Immunoassays rely on an antibody (Ab), or mixture of 
antibodies, for recognition of the molecule being analyzed (the analyte). Immunoassays are 
frequently applied to the analysis of both low molecular ligands and macromolecular drugs, 
and are also applied in such important areas as the quantitation of biomarkers that indicate 
disease progression and immunogenicity of therapeutic drug candidates. The performance 
of immunoassays is critically dependent on the binding properties of the antibody used in the 
analysis, and identification of suitable antibodies is often a major hurdle in assay development. 
Recombinant antibodies will play a major role in future immunoassay development.  
2. Natural and recombinant antibody fragments 
The antibody is the key reagent of an immunoassay and it can be produced by animal 
immunization, hybridoma technology, and/or recombinant techniques. Most, but not all, 
production methods require immunization of an animal with an antigen. An antigen is a 
molecule that can be recognized by the immune system (immunogenicity) and that can be 
bound specifically to an antibody (reactogenicity). Molecules with both immunogenicity and 
reactogenicity are called “complete antigens” and molecules that possess only reactogenicity 
are called “incomplete antigens”. Incomplete antigens, also called haptens, encompass a 
wide variety of molecules, including drugs, explosives, pesticides, herbicides, polycyclic 
aromatic hydrocarbons, and metal ions. These haptens can induce the immune system to 
produce antibodies only when they are covalently conjugated to a larger carrier molecule 
such as a protein.  
Although polyclonal antibodies hold their place as the reagents of choice for general- 
purpose applications in the biological sciences, the volume of serum that can be obtained 
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from immunized animals and batch-to-batch differences in affinity and cross-reactivity 
make them less attractive for quantitative immunoassays. The first milestone for the 
generalized the use of immunoassays was the development of hybridoma technology, 
which overcame problems of heterogeneity and supply (Kohler & Milstein, 1975). While 
traditional monoclonal antibodies are used throughout biological research, many potential 
applications remain unfulfilled. The production of monoclonal antibodies requires 
considerable time, expense and expertise, as well as specialized cell culture facilities. The 
use of animal immunization means that the selection for relevant binding specificities occurs 
in the uncontrolled serum environment. This technology is adequate for stable antigens but 
not for molecules that are highly toxic, not immunogenic in mammals or not stable enough 
to withstand the immune processing steps required for the in vivo immune response. Most 
importantly, when working with monoclonal antibodies, it is not possible to alter or 
improve an antibody’s binding properties without cumbersome procedures that convert the 
molecules to recombinant forms that can be engineered. All these reasons urged the 
development of strategies aimed at the production of recombinant antibodies (rAbs) and 
alternative scaffolds (Gebauer & Skerra, 2009) of smaller dimensions that can be easily 
selected, manipulated and produced using standard molecular biology techniques. 
There are several distinct classes of natural antibodies (IgG, IgM, IgA, and IgE) that provide 
animals with key defenses against pathogenic organisms and toxins. Most immunoassay 
systems rely upon IgG as the immunoglobulin of choice. IgG is bivalent, and its ability to 
bind to two antigenic sites greatly increases its functional affinity and confers high retention 
time on cell surface receptors. The basic structure of an IgG molecule is shown in figure 1. 
Most IgG molecules are composed of two heavy chains (HC) and two light chains (LC), 
which are stabilized and linked by inter- and intra-chain disulfide bonds. The HC and LC 
can be further subdivided into variable regions and constant regions. The antigen binding 
site is formed by the combination of the variable region of the HC and LC. Most IgG 
molecules have two identical antigen binding sites, which are usually flat and concave for 
protein antigens, but which may form a pocket when the antibody has been selected against 
a hapten. Within the HC and LC variable regions are 3 hypervariable regions, also called 
complementary determining regions (CDRs), and 4 frameworks regions (FRs). The greatest 
sequence variation among individual antibodies occurs within the CDRs, while the FRs are 
more conserved. In general, it is assumed that the CDR regions from the LC and HC 
associate to form the antigen binding site. The lower part of the IgG molecule contains the 
heavy chain domains (crystallizable fragment, Fc) that are responsible for important 
biological effector functions. In additional to these conventional antibodies, camelids and 
sharks produce unusual antibodies composed only of heavy chains, also shown in figure 1. 
These peculiar heavy chain antibodies lack light chains (and, in the case of camelid 
antibodies also CH1 domain). Therefore, the antigen binding site of heavy chain antibodies 
is formed only by a single domain that is linked directly via a hinge region to the Fc domain. 
Intact IgG molecules, the bivalent (Fab‘)2, or the monovalent (Fab), all of which contain the 
antigen binding site(s), can be used in immunoassays.  
Recombinant antibody forms have also been developed to facilitate antibody engineering. 
The single chain fragment variable (scFv) molecule is a small antibody fragment of 26-27 
kDa. It contains the complete variable domain of the HC and LC, typically linked by a 15 aa 
long hydrophilic and flexible polypeptide linker. The scFv fragments can also include a His 
tag for purification, an immunodetection epitope and a protease-specific cleavage site. The 
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Fig. 1. Structure of conventional, camelid and shark antibodies and of antibody fragments.  
orientation of the HC and LC domains is critical for binding activity, expression and 
proteolytic stability. Although a vast number of recombinant antibody (rAb) structures have 
been proposed (Holliger & Hudson, 2005), scFv fragments derived from mammalian IgGs 
and the single domain antibodies (sdAbs), which include the VHH from camelid and llama 
and the VH from shark, are the antibody fragments most widely used for both research and 
industrial applications (Kontermann, 2010; Wesolowski et al., 2009).  
3. Principles and selection platforms of rAbs 
Powerful combinatorial technologies have enabled the development of in vitro immune 
repertoires and selection methodologies that can be used to derive antibodies with or 
without the direct immunization of a living host (Hoogenboom, 2005; Marks & Bradbury, 
2004). Recombinant antibody technology has provided an alternative method to engineer 
antibody fragments with the desired specificity and affinity within inexpensive and 
relatively simple host systems. Effective in vitro libraries have been constructed using either 
the entire antigen-binding fragment (Fab) or the single chain variable fragment (scFv), 
which represents the smallest domain capable of mediating antigen recognition. The 
simplest and most widely used antibody libraries utilize the scFv format, although single 
domain heavy chain libraries (VH and VHH) have also been constructed. The construction 
of in vitro libraries using different sources will be reviewed herein. 
3.1 Antibodies from immune antibody libraries 
The first rAbs were derived from pre-existing hybridomas; now, however, rAbs are mostly 
isolated from immune antibody libraries, i.e., antibody libraries generated from genetic 
material derived from immunized animals or naturally infected animals or humans. These 
libraries are biased for binding to the antigen. Thus, affinity maturation takes place in vivo 
and the chances of isolating the high–affinity antibodies are increased. Immune libraries are 
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constructed using HC and LC variable domain gene pools amplified directly from immune 
sources; lymphoid sources include peripheral blood, bone marrow, spleen and tonsil (Huse 
et al., 1989; Schoonbroodt et al., 2005). In contrast to hybridoma technology, which can 
sample no more ~10% of the immune repertoire of an animal, a recombinant immune 
library, when prepared with the appropriate primers, can sample >80% of the immune 
repertoire and the diversity of antibodies that can be derived from a single immunized 
donor is much higher than what is possible using hybridomas. Selection is performed in 
vitro, which enhances the ability to select for rare antibody specificities. In addition, the 
immune repertoires of almost any species can be trapped, even those where hybridoma 
technology has not been described (chicken and llama), is not freely available (rabbit), or is 
not very robust (sheep). Immune libraries can provide higher-affinity binders than non-
immune libraries. Immunizations are generally required for each targeted antigen, although 
multi-antigen immunizations have been performed successfully (Li et al., 2000). Advantages 
and disadvantages of immune libraries include: (1) the ease of preparation compared to 
naïve libraries; (2) the time requirement for animal immunization; (3) the unpredictability of 
the immune response of the animal to an antigen of interest; (4) lack of immune response to 
some antigens; and (5) the necessity of construction of new libraries for each new antigen. 
3.2 Antibodies from nonimmune, synthetic, and semi- synthetic libraries 
Non-immune (naïve) libraries are derived from normal, unimmunized, rearranged V gene 
from the IgM/IgG mRNA of B cells, peripheral blood lymphocytes, bone marrow, spleen or 
tonsil. These libraries are not explicitly biased to contain clones binding to antigens; as such 
they are useful for selecting antibodies against a wide variety of antigens. Using specific sets 
of primers and PCR, IgM and IgG variable regions are amplified and cloned into specific 
vectors designed for selection and screening (Bradbury & Marks, 2004; Marks et al., 1991, 
2004). An ideal naïve library is expected to contain a representative sample of the primary 
repertoires of the immune system, although it will not contain a large proportion of 
antibodies with somatic hypermutations produced by natural immunization. The major 
advantages and disadvantages of using very large naïve libraries are: (1) the large antibody 
repertoire, which can be selected for binders for all antigens including non-immunogenic 
and toxic agents; (2) a shorter time period to binding proteins, because selection is performed 
on an already existing library; (3) low affinity antibodies are obtained from these libraries; and 
(4) it is technically demanding to construct these large non-immune repertoires. Many of these 
disadvantages may be bypassed by using synthetic antibody libraries.  
Synthetic antibody libraries are created by introducing degenerate, synthetic DNA into the 
regions encoding CDRs of the defined variable-domain frameworks. Synthetic diversity 
bypasses the natural biases and redundancies of antibody repertoires created in vivo and 
allows control over the genetic makeup of V genes and the introduction of diversity 
(Hoogenboom & Winter, 1992). A synthetic library has been described that was constructed 
on the basis of existing information on the structure of the antigenic site of proteins and 
small molecules (Persson et al., 2006; Sidhu & Fellouse 2006). 
Semi-synthetic libraries have been constructed by incorporating CDR loops with both 
natural and synthetic diversity into one or more of the antibody framework regions. High 
diversity semi-synthetic repertoires have been generated by introducing partially or 
completely randomized sequences mainly into the CDR3 region of the heavy chain. This 
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process generates highly complex libraries and facilitates the selection of antibodies against 
self-antigens, which are normally removed by the negative selection of the immune system 
(Barbas et al.,1992). An efficient cloning system (in vivo Cre/loxP site specific recombination) 
combined with dual antibody cloning strategies allows construction of very large repertoires 
with about 109-11 individual clones (Sblattero & Bradbury, 2000). Semi-synthetic libraries, 
however, have the disadvantage of always containing a certain number of non-functional 
clones, stemming from PCR errors, stop codons in the random sequence, or improperly 
folded protein products.  
4. In vitro selection procedures for rAbs from combinatorial libraries 
Recombinant antibody technologies provide the investigator with a great deal of control 
over selection and screening conditions and thus permit the generation of antibodies against 
highly specialized antigen conformations or epitopes. The most powerful methods, phage, 
yeast, and ribosomal display technologies, are complementary in their properties and can be 
used with naïve, immunized or synthetic antibody repertoires. 
4.1 Phage display libraries for the isolation of antibodies  
Phage display-based selections are now a relatively standard procedure in many molecular 
biology laboratories. The generation of antibody fragments with high specificity and affinity 
for virtually any antigen has been made possible using phage display. Phage display 
libraries are produced by cloning the pool of genes coding for antibody fragments into 
vectors that can be packed into the viral genome. The rAb is then expressed as an antibody 
fragment on the surface of mature phage particles. Selection of specific antibody fragments 
involves exposure to antigen, which allows the antigen-specific phage antibodies to bind 
their target during the bio-panning. The binding is followed by extensive wash steps and 
subsequent recovery of antigen-specific phage. The phage particles can then be used to 
infect E. coli bacteria. Different display systems can lead to monovalent (single copy) or to 
multivalent (multiple copy) display of the antibody fragment, depending on the type of 
anchor protein and display vector used (Sidhu et al., 2000). The most popular system uses a 
monovalent display vector system, which is convenient for selecting antibodies with higher 
affinity. Monovalent display is achieved by using a direct fusion to a minor viral coat 
protein (pIII). The vector into which most antibody libraries are cloned is a phagemid vector 
that requires a helper phage for the production of phage particles. Use of a phagemid vector 
makes propagation in bacteria much easier to accomplish than would be possible with a 
phage vector (Hust & Dubel, 2005). A general scheme for the isolation of antibody fragments 
by phage display is shown in figure 2. Libraries with 106-11 individual clones can be made 
using recombinant-based protocols. Due to limitations of the E. coli folding machinery, 
complete IgG molecules are very difficult to express in E. coil and display on the surface of 
phage. Therefore, smaller antibody fragments such as Fab, scFv and sdAb are primarily 
used for antibody phage display.  
4.2 Yeast surface display 
Yeast surface display is a powerful method for isolating and engineering antibody 
fragments (Fab, scFv) from immune and non-immune libraries, and has been used to isolate 
recombinant antibodies with binding specificity to variety of proteins, peptides, and small 
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molecules (Boder & Wittrup, 2000; Chao et al., 2006). In this system, antibodies are 
displayed on the surface of yeast Saccharomyces cerevisiae via fusion to an ┙-agglutinin yeast 
adhesion receptor, which is located in the yeast cell wall.  
 
Fig. 2. Schematic diagram for construction of antibody libraries and in vitro display system; 
phage and yeast display.  
Like phage display, yeast display provides a direct connection between genotype and 
phenotype; a plasmid containing the gene of interest is contained within yeast cells, while the 
encoded antibody is expressed on the surface. The display level of each yeast cell is variable, 
with each cell displaying 1x104 to 1x105 copies of the scFv. Variation of surface expression and 
avidity can be quantified using fluorescence activated cell sorting (FACS), which measures 
both antigen binding and antibody expression on the yeast cell surface (Feldhaus et al., 2003). 
The main advantage of yeast surface display over other display technologies is the eukaryotic 
expression bias of yeast, which contains post-translational modification and processing 
machinery similar to that of mammalian cells. Thus, yeast may be better suited for the 
expression of antibodies as compared to prokaryotes such as E. coli. Yeast display libraries 
have been used during the affinity maturation of scFvs from mutagenic libraries (Boder et al., 
2000; Lou et al., 2010; Orcutt et al., 2011). Limiting factors of yeast display include a more 
limited transforming efficacy of yeast as compared to bacteria, which can lead to a smaller 
functional library size (about 107-109 ) than is possible with other display technologies. 
4.3 Ribosomal display 
Ribosomal display is an in vitro selection and evolution technology for proteins and peptides 
from large libraries (Dreier & Pluckthun, 2011; Hanes & Pluckthun, 1997). The general 
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scheme of ribosomal display is shown in figure 3. This display system was developed from a 
peptide-display approach that was extended to screen scFv and scaffold proteins having 
very high affinity for antigen (Kds as low as 10-11 M) from very large libraries (Binz et al., 
2004; Zahnd et al., 2007). The DNA library coding for proteins such as antibodies and 
scaffolds are transcribed in vitro. The mRNA has been engineered without a stop codon; 
therefore, the translated protein remains attached to the peptidyl tRNA and occupies the 
ribosomal tunnel. This allows the protein of interest to protrude out of the ribosome and 
fold. Ribosomal display is performed entirely in vitro, and it has two advantages over other 
selection technologies. First, the diversity of the libraries is not limited by the transformation 
efficiency of bacterial cells (~1x1011 to 1x1013), but only by the number of ribosomes and 
different mRNA molecules present in the test tube. Second, random mutations can be 
introduced easily after each selection round, as no cells must be transformed after any 
diversification step. In ribosomal display, the physical link between the genotype and the 
corresponding phenotype is accomplished by a complex consisting of mRNA, ribosome and 
protein. 
 
Fig. 3. Schematic diagram for isolation of specific antibody fragment from ribosomal display  
Ribosomal display has been used to isolate antibodies that bind to haptens with nanomolar 
affinities (Yau et al., 2003). A summary of the in vitro display systems available to researchers is 
shown in table 1. 
5. Applications of rAbs against low molecular ligands  
A large number of rAbs have been used successfully to develop diagnostic kits, therapeutics 
and biosensors (Holliger et al., 2005; Huang et al., 2010; Kramer & Hock, 2003). The majority 
of the targets were large molecular weight analytes such as proteins and peptides. Prior to 
1990, there were few reports of the isolation of rAbs against low molecular weight molecules 
(haptens) such as drugs of abuse, vitamins, hormones, metabolites, food toxins and 
environmental pollutants, including heavy metals and pesticides. Hapten-specific antibodies 
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Name Display Library size Main applications Advantages Disadvantages 
Phage 
display  
Monovalent 
Multivalent  
10 
10
 to 10
11 
 Abs from natural 
& synthetic 
libraries;  
Affinity 
maturation & 
stability increase  
Easy and 
versatile for 
large rAbs 
panels  
Laborious to 
make large 
libraries; 
Not truly 
monovalent  
Yeast 
surface 
display  
Multivalent 107 Abs from natural 
& synthetic 
libraries; Affinity 
maturation & 
stability increase  
Rapid when 
used in 
combination 
with random 
mutagenesis  
Small rAb 
panels, FACS 
expertise 
required  
Ribosome  
display  
Monovalent 1012 to 1013 Abs from natural 
& synthetic 
libraries; Affinity 
maturation & 
stability increase  
Intrinsic 
mutagenesis, 
fastest of all 
systems  
Small rAb 
panels, limited 
selection scope 
and technically 
sensitive  
Table 1. Comparing the main in vitro selection platforms for isolation of rAbs  
are necessary reagents for the development of immunoassays, immunosensor technologies 
(Charlton et al., 2001), and immunoaffinity chromatography purification columns (Sheedy & 
Hall, 2001). Commercial immunoassays for haptens such as small environmental contaminants 
still rely mostly on polyclonal antibodies rather than monoclonal or recombinant antibodies 
fragments (Sheedy et al., 2007). The complexity and costs associated with the production of 
anti-hapten antibodies by hybridoma technology and the preferential selection of antibodies 
that recognize the conjugated form of the haptens over antibodies that specifically recognize 
free haptens are two of the most important problems that have limited the development and 
application of antibodies that recognize haptens and other low molecules ligands. Moreover, 
some small molecular weight ligands will not trigger the animal immune system even when 
conjugated to a carrier protein, thereby making the production of antibodies against that 
such analytes very difficult.  
In recent years, the production of recombinant antibodies to low molecular weight ligands 
has increased significantly, as shown in table 2. A single methyl or hydroxyl group can have 
a considerable effect on the biological properties of a steroid hormone. Similarly, protein 
phosphorylation, acetylation and sulfation, all of which are relatively simple post-
translational modifications in chemical terms, can dramatically affect signal transduction 
(Bikker et al., 2007; Hoffhines et al., 2006; Kehoe et al., 2006). Antibodies capable of 
discerning such relatively simple chemical modification are of great values in studying these 
effects. The display methods to tailor both affinity and specificity have generated antibodies 
capable of discerning minor difference between related small molecules far better than those 
obtained by immunization.  
6. Improving the specificity and affinity of rAbs to low molecular weight 
ligands 
Although recombinant antibody technology has been able to open the bottleneck in the 
isolation of antibodies against virtually any antigen, it remains difficult to obtain high-
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affinity antibodies against small molecules using immune and naïve libraries. Various 
approaches have been utilized, including identifying the key binding residues, developing 
more effective procedures for selection of the most specific binders and avoiding interfacial 
effects that can compromise the yield and stability of rAbs. 
 
Target Hapten Ab 
format 
Antibody  
library 
In vitro
display 
Reference 
Aflatoxin B1 scFv Naïve Phage (Moghaddam et al., 2001) 
Digoxigenin scFv Naïve Phage (Dorsam et al., 1997) 
Doxorubicin scFv Naïve Phage (Vaughan et al., 1996) 
Estradiol scFv Naïve Phage (Dorsam et al., 1997) 
Indole-3-acetic acid VHH Naïve Phage (Sheedy et al., 2006) 
Fluorescein scFv Naïve Phage (Vaughan et al., 1996) 
Phenyloxazolone scFv Naïve Phage (de Haard et al., 1999) 
Picloram VHH Naïve Ribosome (Yau et al., 2003) 
Progesterone scFv Naïve Ribosome (He et al., 1999) 
Fumosinin B1 scFv Naïve Phage (Lauer et al., 2005) 
Atrazine scFv Immune Phage (Li et al., 2000) 
Azo-dye RR1 VHH Immune Phage (Spinelli et al., 2000) 
Cortisol scFv Immune Phage (Chames & Baty, 1998) 
Digoxin & analogues scFv Immune Phage (Short et al., 1995) 
Isoproturon scFv Immune Phage (Li et al., 2000) 
Mecoprop scFv Immune Phage (Li et al., 2000) 
Simazine scFv Immune Phage (Li et al., 2000) 
Triazine scFv Immune Phage (Kramer, 2002) 
4-Hydroxy- 
3-iodo-5-nitrophenol 
scFv Semi-synthetic Phage (van Wyngaardt et al., 2004) 
Fluorescein scFv Semi-synthetic Phage (van Wyngaardt et al., 2004) 
Microcystin LR scFv Semi-synthetic Phage (Strachan et al., 2002) 
Phtalic acid scFv Semi-synthetic Phage (Strachan et al., 2002) 
Trichlocarbon VHH Naïve Phage (Tabares-da Rosa et al., 2011) 
6-Monoacetylmorphine
but not morphine 
scFv Naïve Phage (Moghaddam et al., 2003) 
Metallic gold Fv Naïve Phage (Watanabe et al.,, 2008) 
Anti-Aluminum VHH Semi-synthetic Phage (Hattori et al., 2010) 
Anti-Cobalt VHH Semi-synthetic Phage (Hattori et al., 2010) 
Anti-Uranium scFv Immune Phage (Zhu et al., 2011) 
Domoic acid scFv Immune Phage (Shaw et al., 2008) 
Azoxystrobin VHH Immune Phage (Makvandi-Nejad et al., 2011) 
Methamidophos scFv Immune Phage (Li et al., 2006) 
Table 2. List of small molecule-specific recombinant antibodies 
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There are, however, unique challenges to the development of antibodies that will perform 
well in assays for low molecular weight ligands. Antigen binding sites are generated by the 
cooperation between the variable domains of the HC and LC (VH/VL). The amino acids of 
FRs compose rigid scaffolds that position the amino acids in the CDRs in loops that extend 
outward from scaffold. These loops play important roles in making contact with the antigen. 
Hapten antigens have remained a great challenge for immunodiagnostics, because the 
hapten portion of the antigen often ends up almost buried inside the concave–shaped 
antigen binding pocket. The extended shape of this binding pocket then facilitates 
additional interactions between amino acid residues in binding site and portions of the 
hapten-protein conjugate present in the bridge between the hapten and the protein 
carrier. These additional interactions mean that the antibody often binds to the much 
more tightly to the hapten-protein conjugate than to the soluble hapten. In our laboratory, 
we have studied this phenomenon with 10 different anti-hapten antibodies. In this study, 
the antibody always bound more tightly to the protein conjugate than to the soluble 
antigen. The differences in affinity ranged from 1.5 to 1600 fold, depending upon the 
antibody being analyzed (Blake et al., 1996, Melton, 2010). Thus, when given a choice, 
anti-hapten antibodies almost always prefer binding to the hapten-protein conjugate, and 
additional soluble hapten is required to inhibit this interaction, thus reducing assay 
sensitivity. Selective panning and affinity maturation are methods available in recombinant 
technology for reducing selective binding of hapten antibodies to the hapten-protein 
conjugate. 
6.1 Panning optimization 
A variety of selection strategies have been reported for the isolation of high affinity rAbs 
against chelated metals and other haptens (Sheedy et al., 2007; Zhu et al., 2011). The most 
successful strategies employed first loose and then increasingly stringent panning 
conditions to enrich the population of phage antibodies as follow: (i) the concentration of 
coating antigen was gradually decreased during successive rounds of panning (Strachan et 
al., 2002; Zhu et al., 2011); (ii) soluble hapten was used to elute ligand-specific antibodies in 
place of the triethylamine more commonly used for elution; (iii) during the panning of 
immune scFv libraries, the conjugate carrier protein and/or other linker peptides were 
included for several intermediate incubation steps at high concentration and subsequently 
decreased to remove phage antibodies that bound to the protein conjugate rather than the 
soluble hapten; (iv) the phage antibodies were incubated with structural analogues of the 
hapten prior to incubation with the immobilized target hapten to eliminate phage antibodies 
with unwanted cross reactivities (Charlton et al., 2001; Zhu et al., 2011). Such panning 
optimization strategies have led to the isolation of antibodies with higher affinity and 
specificity and lower levels of cross-reactivity. For an example from the isolation of 
antibodies to metal-chelate complexes, such subtractive panning strategies were employed 
to isolate an antibody that bound tightly to uranium in complex with 2,9-dicarboxyl-1,10-
phenanthroline, (DCP), but weakly to metal-free DCP. In successive rounds of panning, the 
phage antibody population was incubated with a high concentration of carrier protein (BSA) 
and increasing concentrations of soluble DCP in immunotubes coated with decreasing 
concentrations of a UO22+-DCP-BSA conjugate as shown in table 3.  
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Round of 
Selection 
Percent of maximum 
conjugate coated 
onto immunotubes 
Percent of maximum metal-
free chelator added to the 
phage binding buffer 
Percent of maximum 
carrier protein added to 
the phage binding buffer 
1 100 10 100 
2 100 10 100 
3 10 20 100 
4 10 20 100 
5 1 100 100 
Table 3. General selection strategy for the isolation of scFvs that bind to a metal-loaded but 
not a metal-free chelator (Zhu et al., 2011). 
6.2 In vitro antibody affinity maturation 
The affinity maturation procedure contains two stages: (a) making a modified antibody 
library with a larger diversity than the original library (b) selecting desired antibodies 
molecules from the library using the previously discussed in vitro display and panning 
methods. An antibody’s affinity for its antigen is dependent on the identity and 
conformation of the amino acid sidechains in the CDRs of both the HC and LC. 
Improvement in the antigen-binding affinity can be attained using a number of strategies. 
The mostly common used are random mutagenesis, site-direct mutagenesis and chain 
shuffling. These processes are often referred to as in vitro affinity maturation, to distinguish 
the process from the affinity maturation that takes place in the animal. Although a 
considerable number of successful affinity maturation processes have been reported for 
antibodies against macromolecule antigens like proteins, affinity maturation for low weight 
molecules like haptens and metals is obviously more difficult, and consequently, only a 
limited number of successful studies have thus far been reported. 
6.2.1 Random mutagenesis (Error Prone PCR; E-p PCR) 
Random mutagenesis is the process that most closely mimics the in vivo process of somatic 
hypermutation. This process makes no assumptions as to which sites are the best to mutate 
in order to increase affinity, and it is also technically rather simple to execute. Error prone 
PCR uses low fidelity polymerization conditions to introduce a low level of point mutations 
randomly throughout a wide region of a target gene (e.g. , the entire VH and VL). Error 
prone PCR has been used to demonstrate the effect of mutation frequency on the affinity 
maturation of antibodies against both proteins and small ligands (Daugherty et al., 2000). 
When wild type antibodies to the hapten, diogoxin, were subjected to E-p PCR, the higher 
affinity clones isolated from libraries all contained aromatic residues substitutions in the 
antibody binding site. These resides were thought to be important for hydrophobic 
interaction with the planer aromatic structure of digoxin (Short et al., 1995). A disadvantage 
of E-p PCR is that surface-selection often enriches binders with increased tendency for 
dimerization, especially when using the scFv format. In addition, most of the mutants 
lacked detectable expression or lost antigen-binding affinity. A few mutants lost specificity 
and showed increased cross-reactivity to analogs (Fuji, 2004; Sheedy et al., 2007). Point 
mutation can cause profound effects on the binding affinity and specificity of an antibody 
for its small ligands. The affinity maturation processes reported for anti-hapten scFvs are 
listed in table 4. 
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6.2.2 Site-directed mutagenesis  
In site-directed mutagenesis, the investigator changes specific amino acid residues. Site-
directed mutagenesis is often used in combination with in silico modeling, crystallographic 
data, and ligand docking programs, which allow the investigator to hypothesize about the 
roles that individual binding site amino acid residues have in antigen binding. The CDRs of 
VH and VL are usually targeted for both haptens and protein antigens (Siegel, et al., 2008), and 
mutations in CDRs as opposed to within the framework residues generally contribute more to 
increases in affinity (Orcutt et al., 2011; Short et al., 2002). In one study, the most significant 
increase in affinity was correlated with mutations in the light chain CDR1 even though this 
CDR1 was not contacting the hapten directly (Valjakka et al., 2002). Hapten-specific antibodies 
whose affinity has been increased by site directed mutagenesis are listed in table 4. 
 
Target hapten Fold increase 
in affinity 
Ab format/ 
in vitro display 
Affinity 
maturation 
Reference 
phOx-GABA 290 scFv/Phage Chain shuffling (Marks et al., 1992) 
Cortisol 7.9 scFv/Phage Site-directed (Chames et al., 1998) 
Estradiol-17 ┚ 12 Fab/Phage Site-directed (Kobayashi et al., 2010) 
Fluorescein 2600 scFv/Yeast Ep-PCR /DNA 
-shuffling 
(Boder et al., 2000) 
Testosterone 35 Fab /Phage Site-directed (Valjakka et al., 2002) 
Tacrolimus 15 scFv/Yeast Site-directed (Siegel et al., 2008) 
DOTA-chelate 1000 scFv/Yeast Site-directed (Orcutt et al., 2011) 
Table 4. List of successful affinity maturations of anti-hapten antibodies  
6.3 Shuffling of antibody genes 
Shuffling of antibody genes to create new antibody libraries can be accomplished in several 
ways: chain shuffling, DNA shuffling, and staggered extension processes.  
6.3.1 Chain shuffling 
In this procedure, one of the two chains (VH of VL) is fixed and combined with a repertoire 
of partner chains to yield a secondary library that can be searched for superior pairings 
against antigens. This approach takes advantage of “random” mutations that have been 
introduced into VH and VL germline genes in vivo. Phage display and yeast display are 
often used to facilitate the selection of improved binders from these secondary libraries (Lou 
et al., 2010; Marks, 2004; Persson et al., 2006). This procedure has also been used to increase 
the affinity of anti-hapten antibodies and the results are reviewed in table 4. Chain shuffling 
is only a suitable mutagenesis strategy when VH and VL sequences are available from 
immune libraries. Chain shuffling is, therefore, not useful with naïve libraries since heavy 
and light chains available in these libraries have not been exposed to the antigen of interest. 
6.3.2 DNA shuffling by random fragmentation and reassembly 
DNA shuffling is based on repeated cycles of point mutagenesis, recombination and 
selection, which allows in vitro molecular evolution of protein (Stemmer, 1994). The process 
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mimics somewhat the natural mechanism of molecular evolution (Ness et al., 1999). This 
shuffling technique involves the digestion of a large antibody gene with DNase I to create a 
pool of random DNA fragments. These fragments can then be reassembled into full-length 
genes by repeated cycles of annealing in the presence of DNA polymerase. DNA shuffling 
offers several advantages over more traditional mutagenesis strategies. It uses longer DNA 
sequences and also permits the selection of clones with mutations outside of the antibody 
binding site.  
7. Modification of rAbs fused with signal enhancer proteins  
Antibody engineering enables the preparation of fusion proteins combining scFvs and 
enzymes via the expression of a single scFv-enzyme fusion gene. Such recombinant scFv-
fusion proteins have been reported for numerous applications, including the detection of a 
plant virus (Griep et al., 1999), the human pathogen hantaviruses (Velappan et al., 2007), 
other protein targets such as Bacillus anthraces (Wang et al., 2006), cholera and ricin toxins 
(Swain et al., 2011), and the haptens morphine (Brennan et al., 2003) and 11-deoxycortisol 
(11-DC) (Kobayashi et al., 2006). These fusion proteins provide a much higher signal/noise 
ratio in the ELISA format than conventional enzyme-labeled antibodies because the fusion 
proteins can be obtained as a single molecule species having a 1:1 rAb/enzyme ratio, and 
thus are uncontaminated by unconjugated enzyme and rAb molecules. As an example, the 
sensitivity of a competitive immunoassay for 11-deoxycortisol was 10,000-fold higher when 
an scFv-alkaline phosphatase fusion protein replaced the standard enzyme-labeled 
secondary antibody (Kobayashi et al., 2006; Martin et al., 2006).  
8. Beyond antibody fragments (Scaffold protein)  
Conventional diagnostic immunoassays are limited to the analysis of a few hundred assays 
per day, whereas with antibody microarrays using individually addressable electrodes, 
thousands of assays can be run in parallel (Dill et al., 2004). Antibody fragments are 
providing valuable alternatives to full length mAbs for new biosensing devices because they 
provide small, stable, highly specific reagents against the target antigens. In addition, 
because the recombinant antibody is smaller than the intact IgG, the density of binding sites 
that can be immobilized on the surface of these sensors can be increased. The stability of 
surface-immobilized ligands is also crucial in immunoassay format. Therefore, a great deal 
of interest has been focused on simplifying the antibody scaffold, and molecular engineering 
has pushed the concepts of antibody miniaturization to develop more stable binders that are 
less sterically hindered when immobilized on surfaces. 
To overcome the limitation of antibodies, the several alternative protein frameworks have 
been developed. Design of these protein frameworks, collectively called “scaffolds” or 
“scaffold proteins”, usually involves the adaptation of structurally well-defined polypeptide 
frameworks by the introduction of novel functionality. The new functionality is added to 
those parts of the protein surface that are not considered important for protein folding or 
stability. The recent development of non-biological alternatives to antibodies, including both 
scaffold proteins and plastibodies, may create distinct opportunities for future improvements 
in immunoassay technology. This could be particularly relevant in applications where 
compatibility of the binding probe with organic solvents and the ability to withstand 
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thermal and mechanical stress are required. Currently, there are more than 60 non-antibody 
scaffolds suggested as affinity ligands, primarily for therapeutic and diagnostic purposes 
(Binz et al., 2005a; Caravella & Lugovskoy, 2010; Lofblom et al., 2010; Skerra, 2007). One of 
the current problems with bacterial expression of antibody fragments is that of disulfide 
bond formation, which occurs primarily in the periplasm of bacterial cells. Because of the 
intradomain disulfide bonds required for proper immunoglobulin folding, neither scFvs nor 
Fabs are compatible with intracellular expression and only very stable scFv fragments have 
been expressed in the cytoplasm of E. coli (Martineau & Betton, 1999; Ohage et al., 1999). The 
ideal scaffold therefore should be stable without disulfide bonds, expressed in high amounts 
in E. coli and compatible with current display techniques. The scaffold should contain loops 
or other structures on its surface that can be modified to form the binding site. This can be a 
natural binding site or created de novo. Randomizations made to the binding region should 
be able to generate binders with high specificity and affinity (Binz & Pluckthun, 2005b; 
Gebauer et al., 2009; Gronwall & Stahl, 2009; Kim et al., 2009; Lofblom et al., 2010). All of the 
scaffolds reported to date, including affibodies, anticalins, and designed ankyrin repeats 
(DARPin), can be engineered for interaction with analytes by mimicking the way the immune 
system shuffles sequences to create diversity in loop structures. The goal is to randomize the 
loops without affecting the overall structure and stability of protein. Thus, it is possible to 
engineer binding properties that are totally independent of their original biological function. 
An example of this strategy is the recently developed anticalin with picomolar affinity for 
DTPA-chelated lanthanides, especially YIII (Kim et al., 2009). This anticalin forms a tight non-
covalent complex (with slow dissociation kinetics) under physiological conditions in the 
presence of the chelated metal ion and, after fusion with an appropriate targeting domain; it 
may provide an ideal tool for applications in ‘pretargeting’ radioimmunotherapy. Notably, the 
only established non-Ig scaffold that intrinsically provides pockets and thus allows tight and 
specific complexation of small molecules is the one of the lipocalins. 
9. Conclusion  
Immunoassay techniques provide simple, powerful and inexpensive methods for the 
measurement of small ligands. However, the progress of the development of new 
immunoassays and related immunotechnologies is still limited by the availability of antibodies 
with the desired affinities and specificities for given applications. Advances in molecular 
biology have led to the ability to synthesize antibodies in vitro, completely without the use of 
animals. Recombinant molecular technology that can generate variability, combined with 
high-throughput screening methodologies, can be used to produce engineered antibody-like 
molecules and novel antibody-mimic domains on scaffold proteins. The rAbs fused with other 
functional proteins can enhance the sensitivity of antibody-based assays and reduce the cost 
and labor involved in chemically synthesizing conjugates. Antibody engineering had already 
matured into a technology available to the general scientific community. Further advances will 
lead to better binding proteins that will permit the development of novel, high-throughput 
sensing systems for low molecular weight ligands. 
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